Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Recipient Inclusion Criteria:~* Between 18 and 76 years of age~* Chronic lymphocytic leukemia (CLL):~  * Unmutated IgG VH gene status~ * Mutated IgG VH genes (\> 2% nucleotide change compared to somatic sequence)~ * Complete remission benefit most from allogeneic hematopoietic stem cell transplant (HSCT).~(Physicians will be encouraged to provide aggressive chemotherapy prior to nonmyeloablative transplantation.)~* Mantle cell lymphoma (MCL): Transplant physicians believe subject would benefit from allogeneic HSCT.~* Adequate renal (Cr \< 2.4 mg/dL) and hepatic (Bilirubin \< 3.0 mg/dL, Aspartate aminotransferase (AST) \< 100 IU) function.~* Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment.~* All subjects must provide written informed consent~Donor Inclusion Criteria:~* Genotypically or phenotypically human leukocyte antigen (HLA)-identical.~* Age \< 76 unless cleared by institutional PI~* Capable of giving written, informed consent.~* Must consent to peripheral blood stem cell (PBSC) mobilization with G-CSF and apheresis~Recipient Exclusion Criteria:~* Recipient has a 9 of 10 or 10 of 10 HLA identical donor (high resolution molecular genotyping at HLA A, B, C and DrB1, and DQ)~* Pregnancy~* Lactating~* Serious uncontrolled infection~* HIV seropositivity~* Hepatitis B or C seropositivity~* Cardiac function: ejection fraction \< 40% or uncontrolled cardiac failure~* Pulmonary: Diffusing capacity - carbon monoxide (DLCO) \< 50% predicted~* Liver function abnormalities: elevation of bilirubin to ≥ 3 mg/dL and/or AST \> 100~* Renal: creatinine \> 2.4~* Karnofsky performance score ≤ 60%~* Patients with poorly controlled hypertension (systolic blood pressure \> 150 or diastolic blood pressure \> 90 repeatedly).~* Known life-threatening hypersensitivity to rituximab or other anti-B cell antibodies.~* Inability to comply with the allogeneic transplant treatment.~* Uncontrolled central nervous system (CNS) involvement with disease~Donor Exclusion Criteria:~* Identical twin to subject~* Contra-indication to subcutaneous G-CSF at a dose of 16 mg/kg/d for 5 consecutive days~* Serious medical or psychological illness~* Prior malignancy within the preceding five years, with the exception of non-melanoma skin cancers.~* HIV seropositivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Prophylactic Rituximab (Type: EXPERIMENTAL): Rituximab will be infused after a non-myeloablative transplantation regimen of total lymphoid irradiation (TLI) + anti-thymoglobulin (ATG), with the intention of reducing chronic graft-vs-host disease (cGvHD)

Based on this trial design, predict the completion outcome and termination type (if applicable).